Toplum kaynaklı üropatojenik Escherichia coli suşlarında antibakteriyel direnç

Escherichia coli klinik mikrobiyoloji laboratuvarında hem en sık izole edilen, hem de hemen her organ ve dokuda infeksiyon oluşturabilen bir bakteridir. Hastane ortamında antibakteriyel direnç oranlarının oldukça iyi ortaya konulmasına karşın, toplum kaynaklı infeksiyonlarda ciddi bir veri eksikliği vardır. Bu çalışmada, Sivas Kızılay Tıp Merkezi Mikrobiyoloji Laboratuvarında 2002 yılı içerisinde izole edilen toplum kaynaklı üropatojenik 289 E.coli suşunun antibiyotik duyarlılıkları irdelenmiştir. Kirby-Bauer disk difüzyon testi ile elde edilen sonuçlarımıza göre ampisiline % 82.4, trimetoprim-sulfametoksazole % 56.3, ampisilin/sulbaktama % 44.8, sefuroksime % 31.3, seftriaksona % 8.9, sefepime % 8.1, gentamisine % 6.9, siprofloksasine % 6.9, ofloksasine % 4.6, amikasine % 3.9 ve netilmisine % 1 direnç saptanırken imipenem direnci görülmemiştir. E.coli gibiantibiyotiklere genellikleduyarlı olduğu bilinen bir bakteride elde edilen toplum suşlarına ait budirenç değerleri, antibakteriyel direncin daha şimdiden hangi boyutlara ulaştığını göstermektedir. Ülkemizde antibakteriyel direncin sınırlandırılmasında derhal önlemler alınması gerekmektedir ve infeksiyon hastalıklarının ana platformu olan toplum kaynaklı infeksiyonlar göz ardı edilmemelidir.

Anahtar Kelimeler:

İlaç direnci, bakteriyel, Toplum kökenli enfeksiyonlar, Escherichia coli

PDF

___

1. Aksaray S, Dokuzoğuz B, Güvener E et al: Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in eight hospitals in Turkey, J Antimicrob Chemother 2000;45:695.

2. Ana C, Galesa B, Ronald N et al and the SENTRY Study Group of LatinAmerica:Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in LatinAmerica: Report from the second year of the SENTRYAntimicrobial Surveillance Program (1998), J Antimicrob Chemother 2000;45:295.

3. Ballow CH, Schentag JJ: Trends in antibiotic utilisation and bacterial resistance-Report of the National Nosocomial Resistance Surveillance Group, Diagn Microbiol Infect Dis 1992;15(Suppl 2):37.

4. Barretta SP, SavageaMA, Rebeca MP,GuyotaA,AndrewsN, Shrimptonc SB:Antibiotic sensitivity of bacteria associatedwith community-acquired urinary tract infection in Britain, JAntimicrob Chemother 1999;44:359.

5. Brosnema DA, Adams JR, Pallares R, Wenzel RP: Secular trends in rates and etiology of nosocomial urinary tract infections at a university hospital, J Urol 1993;150:414.

6. Bush K, Jacoby GA, Medeiros AA:A functional classification scheme for beta-lactamases and its correlationwithmolecular structure,Antimicrob Agents Chemother 1995;39:1211.

7. DholakiaN, Rolston KV, Ho DH, Leblanc B, Bodey GP: Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones, Antimicrob Agents Chemother 1994;38:848.

8. Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR: Activity of levofloxacin and ciprofloxacin against urinary pathogens, J Antimicrob Chemother 2001;48:37.

9. GoettschW, Van Pelt W, Nagelkerke N et al: Increasing resistance to fluoroquinolones in E.coli from urinary tract infections in Netherlands, J Antimicrob Chemother 2000;46:223.

10. Goldstein EJC, Citron DM, Hunt GS, Hudspeth M, Merriam CV: Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates, Antimicrob Agents Chemother 1997;41:1193.

11. Howard AJ, Mageea JT, Karen A, Fitzgerald B, Dunstanc FDJ: Factors associatedwith antibiotic resistance in coliformorganisms fromcommunity urinary tract infection in Wales, J Antimicrob Chemother 2001;47:305.

12. Jacobson KL, Cohen SH, Inciardi JF et al: The relationship between antecedent antibiotic use and resistance to extended-spectrumcephalosporins in group I ß-lactamase-producing organisms, Clin Infect Dis 1995;21:1107.

13. Johnson JR, Stamm WE: Urinary tract infections in women: diagnosis and treatment, Ann Intern Med 1989;111:906.

14. Jones RN: Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients, Am J Med 1996;100 (Suppl 6A): 3.

15. Karapınarlı K, Tulumoğlu Ş, Kaya E: Çocuklarda idrar yolu infeksiyonlarından izole edilen etkenler ve antibiyotiklere dirençleri, X. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi, Program ve Özet kitabı s.322, Adana (2001).

16. Kaygusuz S,Apan TZ,Kılıç D:Toplum kökenli üriner sistem infeksiyonu etkeni Gram negatif bakterilerde çeşitli antibiyotiklere direnç,ANKEM Derg 2001;15:753.

17. Keskin K:Yeni bir antibiyotik duyarlılık testi: E-Test, 27. TürkMikrobiyoloji Kongresi, Program ve Özet kitabı s.48, Antalya (1996).

18. Kibar F,Yaman A,Dündar İH, Pekmezci DU:Üriner sistem infeksiyonlarından izole edilen bakteriler ve duyarlılıkları, X. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi, Program ve Özet kitabı s.321, Adana (2001).

19. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, WinnWC Jr: Enterobacteriaceae, “Color Atlas and Textbook of Diagnostic Microbiology, 5. baskı” kitabında s.171, J.B Lippincott Company, Philadelphia (1997).

20. Kristinsson KG: Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci,MicrobDrug Resist 1997; 3:117.

21. Mascellino MT, Farinelli S, Iegri F, Iona E, De Simone C:Antimicrobial activity of fluoroquinolones and other antibiotics on 1116 clinical gram-positive and gram-negative isolates, Drugs Exp Clin Res 1998; 24:139.

22. Moland ES, Thompson KS: Extended spectrum beta-lactamases of Enterobacteriaceae, J Antimicrob Chemother 1994;33:925.

23. Møller JK:Antimicrobial usage and microbial resistance in a university hospital during a seven-year period, J Antimicrob Chemother 1989; 24:983.

24. Mölstad S, Eliasson I, Hovelius B, Kamme C, Schalén C: Beta-lactamase production in the upper respiratory tract flora in relation to antibiotic consumption: a study in children attending day nurseries, Scand J Infect Dis 1988;20:329.

25. National Committee for Clinical Laboratory Standards: Zone Diameter Interpretive Standards and Equivalent MinimumInhibitory Concentration (MIC) Breakpoints for S.pneumoniae, Performance Standards for Antimicrobial Susceptibility, 9.Informational Supplement, Table 2G, NCCLS,Wayne (2002).

26. National Nosocomial Infections Surveillance (NNIS) Report: Data summary from October 1986-April 1996, Am J Infect Control 1996; 24:380.

27. Nava JM, Bella F, Garau J et al: Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: A populationbased study, Clin Infect Dis 1994;9:884.

28. Neu HC: Urinary tract infections, Am J Med 1999;4:63.

29. Pedersena G, Schønheyderb HC, Steffensenc FH, Sørensonc HT: Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia, JAntimicrob Chemother 1999;43:119.

30. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K: Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin- resistant enterococci, Clin Infect Dis 1996; 23:1020.

31. Richard P, Delangle MH, Merrien D et al: Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994;19:54.

32. Seppälä H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P: Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci, Clin Infect Dis 1995;21:1378.

33. Seppala H, Klaukka T, Vuopio-Varkila J et al: The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in groupA streptococci in Finland. Finnish Study Group for Antimicrobial Resistance, N Engl J Med 1997;337:441.

34. Şencan İ, Sevinç ME: Toplum kökenli üropatojen E.coli izolatlarında antimikrobiyal direncin izlemi, Klimik Derg 2002;15:85.

35. Wallace RJ, Steele LC, Brooks DL et al: Ampicillin, tetracycline, and chloramphenicol resistant Haemophilus influenzae in adults with chronic lung disease. Relationship of resistance to prior antimicrobial therapy, Am Rev Resp Dis 1988;137:695.

36. Zhanel GG, Nicolle LE, Gin AS, Karlowsky J, Kabani A, Hoban DJ: Ciprofloxacin and imipenem usage correlates with resistance in Pseudomonas aeruginosa, Can J Infect Dis 1998;9:382.